Qiagen, NeuMoDx Ink Partnership, Merger Agreement

Sep 17, 2018

NEW YORK (GenomeWeb) – Qiagen and NeuMoDx said today they have signed a strategic partnership and merger agreement related to the commercialization of a pair of fully integrated PCR-based molecular diagnostic systems.

As part of their strategic partnership, Qiagen will initially distribute the NeuMoDx 288 (high-throughput) and NeuMoDx 96 (mid-throughput) systems in Europe and other markets outside the US, where NeuMoDx will continue to market the products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Main menu